KINIKSA PHARMACEUTICALS INTERNATIONAL PLC. - CLASS A (KNSA)

Shares of NASDAQ KNSA opened at $74.34 on Thursday. The company’s fifty day moving average is $59.04 and its 200-day moving average is $51.13. The stock has a market cap of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07.

Sei Investments Co. increased its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 30.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 284,005 shares of the company's stock afte

Prefer clear visual charts instead of another page of earnings tables and footnotes? See Kiniksa Pharmaceuticals International's full financial picture with a focus on valuation in our company report for Kiniksa Pharmaceuticals International. NasdaqGS:KNSA Trailing 12-Month Earnings & Revenue ...

A Kiniksa Pharmaceuticals holder plans to sell 3,673 Class A shares under Rule 144, valued at $299,092.00, with 48,289,273 Class A shares outstanding on NASDAQ.

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... On October 23, 2023, Kiniksa Pharmaceuticals (KNSA) received a positive analyst rating update from Canaccord Genuity.